Skip to main content

Multiple Myeloma Prognosis Calculator

Multiple Myeloma Prognosis (ISS)

Understanding the International Staging System (ISS)

The International Staging System (ISS) is the standard prognostic tool for multiple myeloma. It uses two simple blood tests - serum β2-microglobulin and serum albumin - to classify patients into three stages with different survival outcomes. This staging system helps doctors determine prognosis and plan appropriate treatment strategies.

What is the International Staging System?

The International Staging System (ISS) was developed through analysis of over 10,750 patients from 17 institutions worldwide. It provides a simple, reliable way to stratify patients into three prognostic groups based on serum β2-microglobulin and albumin levels at diagnosis.

ISS Stages and Prognosis

Stage I

  • β2-microglobulin < 3.5 mg/L AND
  • Albumin ≥ 3.5 g/dL
  • Median survival: 62 months

Stage II

  • Neither Stage I nor Stage III
  • Median survival: 44 months

Stage III

  • β2-microglobulin ≥ 5.5 mg/L
  • Median survival: 29 months

Clinical Significance

The ISS staging system:

  • Was validated across North America, Europe and Asia
  • Works equally well for patients under and over 65 years old
  • Is effective for both standard chemotherapy and high-dose therapy patients
  • Provides more equal distribution of patients across stages compared to the older Durie/Salmon system
  • Uses simple, widely available laboratory tests (β2-microglobulin and albumin)

When to Use ISS Staging

ISS staging is typically used:

  • At initial diagnosis
  • Before starting treatment
  • For research purposes
  • To monitor disease progression

Factors Affecting Prognosis

β2-microglobulin levels can be affected by

  • Tumor burden
  • Kidney function
  • Age
  • Overall health status

Albumin levels can be affected by

  • Nutritional status
  • Liver function
  • Inflammation
  • Chronic illness

Clinical Applications

The ISS is particularly useful for:

  • Initial staging
  • Treatment planning
  • Clinical trial eligibility
  • Comparing outcomes across centers

Start calculating now to better understand your multiple myeloma prognosis!

References:

  1. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.